Journal article icon

Journal article

Sodium-glucose co-transporter 2 (SGLT2) inhibitor: comparing trial data and real-world use

Abstract:

The first cardiovascular safety trial in the sodium-glucose co-transporter-2 (SGLT2) inhibitor drug class, the Empagliflozin Cardiovascular Outcomes and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) trial, demonstrated significant cardiovascular risk reduction with empagliflozin. It is currently not clear what proportions of people with type 2 diabetes (T2DM) have the same high cardiovascular risk as those included in the trial, and will therefore be likely to experience the same cardiovasc...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Publisher copy:
10.1007/s13300-017-0254-7

Authors


More by this author
Role:
Author
ORCID:
0000-0002-6833-9399
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Primary Care Health Sciences
Department:
Unknown
Role:
Author
ORCID:
0000-0002-8553-2641
Publisher:
Springer
Journal:
Diabetes Therapy More from this journal
Volume:
8
Issue:
2
Pages:
365-376
Publication date:
2017-03-21
DOI:
EISSN:
1869-6961
ISSN:
1869-6953
Pmid:
28324484
Language:
English
Keywords:
Pubs id:
pubs:1013754
UUID:
uuid:61a30f28-61c3-4e93-8c38-536f2672f581
Local pid:
pubs:1013754
Source identifiers:
1013754
Deposit date:
2019-11-29

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP